Product
Prolia®
Aliases
Denosumab Injection
6 clinical trials
4 indications
Indication
OsteoporosisIndication
Healthy Control ParticipantsIndication
PostmenopausalIndication
Postmenopausal Women With OsteoporosisClinical trial
Randomized, Doubel-blinded, Parallel, Active-controlled Phase III Study, to Evaluate the Efficacy and Safety of CMAB807 Treatment Compared With Prolia® in Chinese Postmenopausal Women With Osteoporosis at High Risk of Fracture.Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Randomised, Double Blind, Multicentre Phase III Study to Assess the Efficacy and Safety of RGB-14-P Compared to Prolia® in Women With Postmenopausal OsteoporosisStatus: Completed, Estimated PCD: 2023-10-02
Clinical trial
A Randomized, Double-blind, Two-arm, Single-dose, Parallel-Group Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy VolunteersStatus: Completed, Estimated PCD: 2023-10-06
Clinical trial
A Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (Prolia®) in Patients With Postmenopausal OsteoporosisStatus: Completed, Estimated PCD: 2022-12-31
Clinical trial
A Randomized, Double-Blind, International Multicentre, Parallel-Controlled Phase III Clinical Study to Evaluate Recombinant Anti-RANKL Human Monoclonal Antibody Injection (HLX14) Versus Denosumab Injection (Prolia®) in Postmenopausal Women With Osteoporosis at High Risk of FractureStatus: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Randomized, Double-Blind, Multicenter, Parallel-Arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With OsteoporosisStatus: Active (not recruiting), Estimated PCD: 2024-06-20